Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase IIb, Non-inferiority Proof of Principle Trial
Latest Information Update: 15 Dec 2023
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- Acronyms RISAPS
- 06 Dec 2023 Phase of the study changed to Phase II .
- 06 Dec 2023 Planned number of patients changed from 140 to 40.
- 06 Dec 2023 Planned End Date changed from 1 Mar 2025 to 2 Feb 2025.